000199585 001__ 199585
000199585 005__ 20180913062530.0
000199585 0247_ $$2doi$$a10.1098/rstb.2013.0430
000199585 022__ $$a0962-8436
000199585 02470 $$2ISI$$a000336094600004
000199585 037__ $$aARTICLE
000199585 245__ $$aWho will develop new antibacterial agents?
000199585 260__ $$bRoyal Soc$$c2014$$aLondon
000199585 269__ $$a2014
000199585 300__ $$a7
000199585 336__ $$aReviews
000199585 520__ $$aThe golden age of antimicrobial drug development is a distant memory, and the likelihood of there being another seems slim. In part, this is because the pharmaceutical industry, which has now adopted an unsustainable business model, abandoned the anti-infective sector, and the pipeline is almost empty. The contribution to this crisis of national governments, health agencies and funders also merits discussion. Much of the basis for drug discovery is funded by the public sector, thereby generating intellectual property and leads for drug development that are often not pursued owing to funding gaps. In particular, the cost of testing drug efficacy in clinical trials is beyond the means of most companies and organizations. Lack of a concerted international effort to develop new antimicrobials is particularly alarming at a time when multidrug-resistant bacteria threaten all areas of human medicine globally. Here, the steps that led to this situation are retraced, and some possible solutions to the dilemma are proposed.
000199585 6531_ $$aantibiotics
000199585 6531_ $$adrug resistance
000199585 6531_ $$adrug discovery
000199585 6531_ $$apharmaceutical industry
000199585 6531_ $$abiotechnology
000199585 700__ $$g177247$$0243892$$aCole, Stewart T.
000199585 773__ $$j369$$tPhilosophical Transactions Of The Royal Society B-Biological Sciences$$k1645
000199585 909C0 $$xU11742$$0252302$$pUPCOL
000199585 909CO $$pSV$$preview$$ooai:infoscience.tind.io:199585
000199585 917Z8 $$x164606
000199585 937__ $$aEPFL-REVIEW-199585
000199585 973__ $$rREVIEWED$$sPUBLISHED$$aEPFL
000199585 980__ $$aREVIEW